

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
櫻井晃洋	遺伝性腫瘍に係る保険診療の最新動向と課題	平沢晃	「遺伝子医学」別冊	メディカル・ドゥ	東京	2022	333-338
櫻井晃洋	遺伝性乳癌の遺伝カウンセリング	戸井雅和	乳癌診療state of arts-科学にもとづく最新診療-	医歯薬出版	東京	2022	276-279
新井正美	総説5. 遺伝性乳癌と遺伝学的検査, 遺伝カウンセリング	日本乳癌学会編	乳癌診療ガイドライン②疫学・診断編2022年版	金原出版	東京	2022	108-123
新井正美	CQ3 BRCA病的バリエーションをもつ女性にリスク低減乳房切除術(RRM)は勧められるか?	日本乳癌学会編	乳癌診療ガイドライン②疫学・診断編2022年版	金原出版	東京	2022	124-130
新井正美	CQ4 BRCA病的バリエーションをもつ女性にリスク低減卵管卵巣摘出術(RRSO)は勧められるか?	日本乳癌学会編	乳癌診療ガイドライン②疫学・診断編2022年版	金原出版	東京	2022	131-139
平沢 晃	網羅的遺伝子解析と生殖細胞系列用の情報	松浦成昭、櫻井晃洋、石岡千加史、西尾和久、全国がんプロ協議会	がんゲノム医療やさしい系統講義	メディカル・サイエンス・インターナショナル	東京	2023	179-184
山本英喜、平沢晃	BRCA遺伝子変異陽性腫瘍	石岡千加史、関根郁夫、安藤雄一、伊豆津宏二	がん最新の薬物療法 2023-2024	南江堂	東京	2023	239-246

平沢 晃	がんゲノム医療における「連携」ー主に患者,家族・血縁者の連携にかかる課題についてー全国がんプロ協議会・ゲノム医療部会報告	全国がんプロ協議会・ゲノム医療部会	癌と化学療法	癌と化学療法社	東京	2022	1000-1001
平沢 晃	疾患各論 HBOC 遺伝性乳癌卵巣癌(Hereditary breast and ovarian cancer:HBOC)	平沢 晃	「遺伝子医学」別冊	メディカル・ドウ	東京	2022	92-98
植野さやか, 平沢 晃	BRCA病的パリアントが検出された際の対応	大道正英、亀井良正、久慈直昭	臨床婦人科産科	医学書院	東京	2022	324-331
小川千加子、増山寿、平沢 晃	がんゲノム医療とgermline findingsの取り扱い	澤井英明、平沢 晃	産婦人科医が知っておきたい臨床遺伝学のすべて	医学書院	東京	2022	111-118
吉田玲子	遺伝性腫瘍の基礎知識	平沢 晃	「遺伝子医学」別冊	メディカル・ドウ	東京	2022	325-333
吉田玲子	遺伝性腫瘍の遺伝学的検査	難波栄二、要匠、井本逸勢	「遺伝子医学」44号 vol.13 No.2	メディカル・ドウ	東京	2023	79-86
吉田玲子	遺伝領域(担当リーダー)	厚労科研 櫻井班、JOHBOC	遺伝性乳がん卵巣がんを知ろう!みんなのためのガイドブック	金原出版	東京	2022	
櫻井晃洋、平沢 晃、鈴木美慧、吉田玲子	Beyond BRCA ~幅広い遺伝性腫瘍と未発症者も対象にした遺伝医療のプレジジョン・メディスンをめざして		月刊インナービジョン 4月号	インナービジョン	東京	2023年	69-76
Masuda K, Satake M, Aoki D	Hereditary Ovarian Cancer	Nakamura S, Aoki D, Miki Y	Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice	Springer Nature Singapore	Singapore	2021	93-106

Murakami W, <u>Tozaki M</u> , McCann KE, Lee-Felker S	Risk-based breast cancer screening	Nakamura S, Aoki D, Miki Y	Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice	Springer Nature Singapore	Singapore	2021	107-128
Kotake R, Tsuchida Y, Kida K, <u>Yamauchi H</u>	Risk-reducing mastectomy (RRM)	Nakamura S, Aoki D, Miki Y	Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice	Springer Nature Singapore	Singapore	2021	169-182
Okazawa-Sakai M, <u>Hirasawa A</u>	Germline findings through precision oncology	Nakamura S, Aoki D, Miki Y	Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice	Springer Nature Singapore	Singapore	2021	211-226
<u>Sakurai A</u>	Germline findings from genetic testing for breast cancer	Nakamura S, Aoki D, Miki Y	Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice	Springer Nature Singapore	Singapore	2021	227-242
<u>Arai M</u>	Hereditary breast and ovarian cancer (HBOC) database	Nakamura S, Aoki D, Miki Y	Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice	Springer Nature Singapore	Singapore	2021	243-258
Ri I, Muto K	Ethical issues: overview in genomic analysis and clinical context	Nakamura S, Aoki D, Miki Y	Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice	Springer Nature Singapore	Singapore	2021	259-280
Sunada S, Miki Y	PARP inhibitors: mechanism of action	Nakamura S, Aoki D, Miki Y	Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice	Springer Nature Singapore	Singapore	2021	281-292
<u>櫻井晃洋</u>	遺伝性腫瘍	田中伸哉、西原広史	がんゲノム病理テキスト	文光堂	東京	2022	40-45

平沢 晃, 浦川優作	遺伝性乳癌卵巣 癌(Hereditary breast and ovarian cancer:HBOC)	平沢晃	「遺伝子医学」 別冊 遺伝性腫 瘍学入門	メディカルド ゥ	大阪	2022	92-98
坂井美佳, 平沢 晃	がん薬物療法 分 子標的薬剤- PARP阻害剤.	渡部 洋	婦人科がん薬物 療法パーフェクト ガイド	診断と治療 社	東京	2021	6-10
浦川優作, 平沢 晃	遺伝性腫瘍-最近 の動向. 妊孕性温 存のすべて	柴原浩章	妊孕性温存のす べて	中外医学 社	東京	2021	80-87
吉田玲子	遺伝性腫瘍のマネ ージメント	臨床遺伝 専門医制 度委員会	臨床遺伝専門 医テキスト5 臨 床遺伝学腫瘍 領域	診断と治療 社	東京	2021	69-75
吉田玲子	多遺伝子パネル 検査の利活用 の実際	平沢晃	遺伝子医学別 冊 遺伝性腫瘍 の基礎知識	メディカルド ゥ	大阪	2022	325-332
櫻井晃洋	遺伝学的検査によ り得られる遺伝情 報の取扱い	中谷中	臨床病理レビュ ー特集第165号	克誠堂出 版	東京	2021	57-62
櫻井晃洋	遺伝性腫瘍と遺伝 カウンセリング	日本臨床腫 瘍学会	入門腫瘍内科 学第3版	南江堂		2020	17-18

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Masui T, Ito T, Komoto I, Kojima S, Kasai Y, Tanabe M, Hirano S, Okusaka T, Ichikawa Y, Kinugasa Y, Kokudo N, Kudo A, <u>Sakurai A</u> , Suhihara K, Date H, Haruma K, Hijioka S, Hirata K, Yamano Y, Sakamine M, Kikuchi T, Fukushima M, Imamura M, Uemoto S, JNETS Registry Study Group	Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan.	Int J Clin Oncol	27	840-849	2022

Minoura Y, Takahashi M, Maeda H, Sasaki S, Kuwahara S, Tachikawa H, Yamamoto M, Tomioka N, Watanabe K, <u>Sakurai A</u>	Significance of prostate/pancreatic/skin-cancer family history for detecting BRCA2 pathogenic variant carriers.	Breast Cancer	29	808-813	2022
<u>櫻井晃洋</u>	遺伝情報の臨床活用-遺伝子例外主義からの脱却.	日本臨床検査医学会誌	71	13-16	2023
Akahane T, Masuda K, <u>Hirasawa A</u> , <u>Kobayashi Y</u> , Ueki A, Kawaida M, Misu K, Nakamura K, Nagai S, Chiyoda T, Yamagami W, Hayashi S, Kataoka F, Banno K, Sugano K, Okita H, Kosaki K, Nishihara H, <u>Aoki D</u> .	TP53 variants in p53 signatures and the clonality of STICs in RRSO samples.	J Gynecol Oncol	33	e50	2022
<u>Kobayashi Y</u> , Masuda K, <u>Hirasawa A</u> , Takehara K, Tsuda H, Watanabe Y, Oda K, Nagase S, Mandai M, Okamoto A, Yaegashi N, Mikami M, Enomoto T, <u>Aoki D</u> , Katabuchi H; Working Group on Clinical Practice for Cancer Genomic Medicine and HBOC, Japan Society of Gynecologic Oncology.	Current status of hereditary breast and ovarian cancer practice among gynecologic oncologists in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO).	J Gynecol Oncol	33	e61	2022
Oda K, <u>Aoki D</u> , Tsuda H, Nishihara H, Aoyama H, Inomata H, Shimada M, Enomoto T	Japanese nationwide observational multicenter study of tumor BRCA1/2 variant testing in advanced ovarian cancer	Cancer Sci	114	271-280	2023
<u>戸崎光宏</u> , <u>村上和香奈</u>	HBOC未発症者に対する乳房MRI検診:欧米の現状について	日本乳癌検診学会誌	31	157-161	2022

Sekine M, Enomoto T, <u>Arai M</u> , Yokoyama S, Nomura H, Nishino K, Ikeuchi T, Kuriyama Y, <u>Nakamura S</u> ; Registration Committee of the Japanese Organization of Hereditary Breast and Ovarian Cancer	Correlation between the risk of ovarian cancer and BRCA recurrent pathogenic variants in Japan	J Hum Genet	67(5)	267-272	2022
Sekine M, Enomoto T, <u>Arai M</u> , Den H, Nomura H, Ikeuchi T, <u>Nakamura S</u> , and the Registration Committee of the Japanese organization of hereditary breast and ovarian cancer	Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: Optimal timing to carry out risk-reducing salpingo-oophorectomy	J Gynecol Oncol	33(4)	e46	2022
Nakamura Y, Kubota J, Nishimura Y, Nagata K, Nishimura M, Daino K, Ishikawa A, Kaneko T, Mashimo T, Kokubo T, Takabatake M, Inoue K, Fukushi M, <u>Arai M</u> , Saito M, Shimada Y, Kakinuma S, Imaoka T	BrcalL63X /+ rat is a novel model of human BRCA1 deficiency displaying susceptibility to radiation-induced mammary cancer	Cancer Sci	113 (10)	3362-3375	2022
Ohsumi S, <u>Nakamura S</u> , Miyata H, Watanabe C, Den H, <u>Arai M</u>	Risk-reducing mastectomy for women with hereditary breast and ovarian cancer (HBOC): analytical results of data from the Japanese Organization of HBOC	Jpn J Clin Oncol	52(11)	1265-1269	2022
Sasaki R, Horimoto Y, Saeki H, Sato S, Sano K, Shikama N, Ueno M, Saito M, <u>Arai M</u>	Lessons Learned in Practice with Li-Fraumeni Syndrome: LFS-Related Breast Cancer Treatment Strategy and Establishment of a Surveillance System	Juntendo Medical Journal	68(4)	405-412	2022

Utsunomiya H, Akazawa Y, Ueyama H, Iwano T, Yamamoto M, Uchida R, Oki S, Suzuki N, Abe D, Ikeda A, Takeda T, Ueda K, Hojo M, Yube Y, Kaji S, Okano S, Tsuyama S, Eguchi H, Okazaki Y, <u>Arai M</u> , Fukunaga T, Yao T, Nagahara A	Gastric Juvenile Polyposis with Intramucosal Cancer Diagnosed by Magnifying Endoscopy with Narrow-band Imaging: A Case Report	Intern Med		1612-23	2023
Kang EY, <u>Hirasawa A</u> , et al.	CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.	Cancer	129(5)	697-713	2023
村上和香奈、 <u>戸崎光宏</u>	BRCA 病的バリエント(変異)陽性者に対する乳房MRI	乳癌の臨床	37	17-23	2022
Okazawa-Sakai M, Yamamoto Y, Futagawa M, Okamura M, Miyawaki S, Nishina T, Takehara K, Kozuki T, Tomida S, Hyodo I, Ohsumi S, <u>Hirasawa A</u> .	Handling of Germline Findings in Clinical Comprehensive Cancer Genomic Profiling.	Acta Med Okayama	76(6)	673-678	2022
Murumägi A, Ungureanu D, Khan S, Arjama M, Välimäki K, Ianevski A, Ianevski P, Bergström R, Dini A, Kanerva A, Koivisto-Korander R, Tapper J, Lassus H, Loukovaara M, Mägi A, <u>Hirasawa A</u> , Aoki D, Pietiäinen V, Pellinen T, Bützow R, Aittokallio T, Kallioniemi O.	Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.	Br J Cancer	128(4)	678-690	2023
Ueno S, Sudo T, <u>Hirasawa A</u> .	TM: Functions of ATM Kinase and Its Relevance to Hereditary Tumors.	Int J Mol Sci	23(1)	523	2022

Ogawa C, <u>Hirasawa A</u> , Sogawa R, Hasuoka K, Tomida S, Futagawa M, Urakawa Y, Kochi M, Yamamoto H, Nakamura K, Masuyama H.	Liquid Biopsy Revealed HBOC Pedigree and Led to Medical Management Among the Relatives.	Acta Med Okayama	76(4)	479-483	2022
Ogawa C, <u>Hirasawa A</u> , Ida N, Nakamura K, Masuyama H.	Hereditary Gynecologic Tumors and Precision Cancer Medicine.	J Obstet Gynaeco Res	48(5)	1076-1090	2022
Minamoto A, Yamada T, Shimada S, Kinoshita I, Aoki Y, Oda K, Ueki A, Higashigawa S, Morikawa M, Sato Y, <u>Hirasawa A</u> , Ogawa M, Kondo T, Yoshioka M, Kanai M, Muto M, Kosugi S.	Current status and issues related to secondary findings in the first public insurance covered tumor genomic profiling in Japan: multi-site questionnaire survey.	J Hum Genet	67(10)	557-563	2022
<u>Yoshida R</u> , Nakamura S	Association of TP53 clonal hematopoiesis with indeterminate potential with the development of myeloid neoplasms after rucaparib treatment.	Ann Transl Med.	23	1292	2022
Nagashima M, Ishikawa T, Asami Y, Hirose Y, Shimada K, Miyagami S, Mimura T, Onuki M, Morioka M, Izumi M, <u>Yoshida R</u> , Yamochi T, Taruno K, <u>Nakamura S</u> , Sekizawa A, Matsumoto K.	Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience.	JJCO		DOI: 10.1093/jjco/hyad020	2023

<p>Masui T, Ito T, Komoto I, Kojima S, Kasai Y, Tanabe M, Hirano S, Okusaka T, Ichikawa Y, Kinugasa Y, Kokudo N, Kudo A, <u>Sakurai A</u>, Suhihara K, Date H, Haruma K, Hijioka S, Hirata K, Yamano Y, Sakamine M, Kikuchi T, Fukushima M, Imamura M, Uemoto S, JNETS Registry Study Group</p>	<p>Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan.</p>	<p>Int J Clin Oncol</p>	<p>27</p>	<p>840-849</p>	<p>2022</p>
<p>Ito T, Masui T, Komoto I, Doi R, Osamura RY, <u>Sakurai A</u>, Ikeda M, Takano K, Igarashi H, Shimatsu A, Nakamura K, Nakamoto Y, Hijioka S, Morita K, Ishikawa Y, Oike N, Kasashima A, Kushima R, Kojima M, Sasano H, Hirano S, Mizuno N, Aoki T, Aoki G, Otsuka T, Okumura T, Kimura Y, Kudo A, Konishi T, Matsumoto I, Kobayashi N, Fujimori N, Honma Y, Morizane C, Uchino S, Horiuchi K, Yamazaki M, Matsubayashi J, Sato Y, Sekiguchi M, Abe S, Okusaka T, Kida M, Kimura M, Tanaka M, Majima Y, Jensen RT, Hirata K, Imamura M, Uemoto S</p>	<p>JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis.</p>	<p>J Gastroenterol</p>	<p>56</p>	<p>1033-1044</p>	<p>2021</p>

Kikuchi J, Takeda K, Tanabe H, Hatanaka K, Ohhara Y, Amano T, Hatanaka KC, Hatanaka Y, Mitamura T, Yabe I, Endoh A, Komatsu Y, Matsuno Y, Manabe A, <u>Sakurai A</u> , Takahashi M, Naruse H, Torimoto Y, Dosaka-Akita H, Kinoshita I	Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers with no standard drug therapy in Hokkaido area of Japan.	Jpn J Clin Oncol	51	753-761	2021
Yamashita K, Fukushima H, Teramoto M, Okita K, Ishikawa A, <u>Sakurai A</u> , Akagi K, Nakase H	Interval between first cancer and genetic diagnosis in Lynch syndrome probands	Intern Med	60	2719-2724	2021
Matsushita R, <u>Sakurai A</u> , Minamitani K, Yamazaki M, Uchino S	Extra-endocrine phenotypes at infancy in multiple endocrine neoplasia type 2B: A case series of six Japanese patients.	Clin Pediatr Endocrinol	30	195-200	2021
Yonamine M, Wasano K, Alta Y, Sugawara T, Takahashi K, Kawakami Y, Shimano H, Nishiyama H, Naruse M, Okamoto T, Matsuda T, Kosugi S, Yamada M, Tanabe A, Watanabe A, Kimura N, Nakamura E, <u>Sakurai A</u> , Shiga K, Takekoshi K	Prevalence of germline variants in a large cohort of Japanese patients with pheochromocytoma and/or paraganglioma.	Cancers	13	4014	2021
吉田玲子, 平沢晃, 山内英子, 中村清吾, 櫻井晃洋	生殖細胞系列多遺伝子パネル検査による遺伝性腫瘍診断の有用性.	日本遺伝カウンセリング学会誌	42	241-248	2021
Abe K, Ueki A, Urakawa Y, Kitago M, Yoshihama T, Nanki Y, Kitagawa Y, <u>Aoki D</u> , Kosaki K, <u>Hirasawa A</u>	Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report.	Hered Cancer Clin	19(1)	5	2021

Kobayashi Y, <u>Hirasawa A</u> , Chiyoda T, Ueki A, Masuda K, Misu K, Kawaida M, Hayashi S, Kataoka F, Banno K, Kosaki K, <u>Aoki D</u>	Retrospective evaluation of risk-reducing salpingo-oophorectomy for <i>BRCA1/2</i> pathogenic variant carriers among a cohort study in a single institution.	Jpn J Clin Oncol	51(2)	213-217	2021
Yoshimura A, Yokoyama S, Iwata H, takaiso N, Nomizu T, <u>Arai M</u> , Nakamura S	Incidence of contralateral and ipsilateral breast cancers and prognosis in <i>BRCA1/2</i> pathogenic variant carriers based on the Japanese HBOC Consortium registration	J Hum Genet	66(4)	379-387	2021
Hatamori H, Chino A, <u>Arai M</u> , Ide D, Saito S, Igarashi M, Kita M, Nakajima T, Kawachi H, Fujisaki J	Malignant potential of colorectal neoplasms in Lynch syndrome: an analysis of 325 lesions endoscopically treated at a single institute	Jpn J Clin Oncol	51(5)	737-743	2021
Tomita N, Ishida H, Tanakaya K, Yamaguchi T, Kumamoto K, Tanaka T, Hinoi T, Miyakura Y, Hasegawa H, Takayama T, Ishikawa H, Nakajima T, Chino A, Shimodaira H, Hirasawa A, Nakayama Y, Sekine S, Tamura K, Akagi K, Kawasaki Y, Kobayashi H, <u>Arai M</u> , Itabashi M, Hashiguchi Y, Sugihara K, Japanese Society for Cancer of the Colon, Rectum	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer	Int J Clin Oncol	26	1353-1419	2021
Sekine M, Enomoto T, <u>Arai M</u> , Yokoyama S, Nomura H, Nishino K, Ikeuchi T, Kuriyama Y, Nakamura S; Registration Committee of the Japanese Organization of Hereditary Breast and Ovarian Cancer	Correlation between the risk of ovarian cancer and <i>BRCA</i> recurrent pathogenic variants in Japan	J Hum Genet	67(5)	267-272	2022

Sekine M, Enomoto T, <u>Arai M</u> , Den H, Nomura H, Ikeuchi T, Nakamura S, and the Registration Committee of the Japanese organization of hereditary breast and ovarian cancer	Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: Optimal timing to carry out risk-reducing salpingo-oophorectomy	J Gynecol Oncol		in press	2022
村上和香奈、 <u>戸崎光宏</u>	BRCA 病的バリエーション(変異)陽性者に対する乳房MRI	乳癌の臨床	37	17-23	2022
Yamamoto H, <u>Hirasawa A.</u>	Homologous Recombination Deficiencies and Hereditary Tumors.	I Int J Mol Sci	23	348	2021
Abe K, Kitago M, Kitagawa Y, <u>Hirasawa A.</u>	Hereditary pancreatic cancer.	Int J Clin Oncol	26	1784-1792	2021
Tomita N, Ishida H, Tanakaya K, Yamaguchi T, Kumamoto K, Tanaka T, Hinoi T, Miyakura Y, Hasegawa H, Takayama T, Ishikawa H, Nakajima T, Chino A, Shimodaira H, <u>Hirasawa A</u> , Nakayama Y, Sekine S, Tamura K, Akagi K, Kawasaki Y, Kobayashi H, Arai M, Itabashi M, Hashiguchi Y, Sugihara K.	Japanese Society for Cancer of the Colon, Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.	Int J Clin Oncol	26	1353-1419	2021
Futagawa M, Yamamoto H, Kochi M, Urakawa Y, Sogawa R, Kato F, Okazawa-Sakai M, Ennishi D, Shinozaki K, Inoue H, Yanai H, <u>Hirasawa A.</u>	Retroperitoneal leiomyosarcoma in a female patient with a germline splicing variant RAD51D c.904-2A>T: a case report.	Hered Cancer Clin Pract	19(1)	48	2021

<p>Ueki A, Sugano K, Misu K, Aimonio E, Nakamura K, Tanishima S, Tanaka N, Mikami S, Hirasawa A, Ando M, Yoshida T, Oya M, Nishihara H, Kosaki K.</p>	<p>Germline Whole-Gene Deletion of FH Diagnosed from Tumor Profiling.</p>	<p>Int J Mol Sci</p>	<p>22(15)</p>	<p>7962</p>	<p>2021</p>
<p>Kang EY, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, Anglesio MS, Leung B, Tang K, Lambie N, Pavanello M, Da-Anoy A, Lambrechts D, Loverix L, Olbrecht S, Bisinotto C, Garcia-Donas J, Ruiz-Llorente S, Yagüe-Fernandez M, Edwards RP, Elishaev E, Olawaiye A, Taylor S, Ataseven B, du Bois A, Harter P, Lester J, Høgdall CK, Armasu SM, Huang Y, Vierkant RA, Wang C, Winham SJ, Heublein S, Kommos FKF, Cramer DW, Sasamoto N, van-Wagensveld L, Lycke M, Mateoiu C, Joseph J, Pike MC, Odunsi K, Tseng CC, Pearce CL, Bilic S, Conrads TP, Hartmann A, Hein A, Jones ME, Leung Y, Beckmann MW, Ruebner M, Schoemaker MJ, Terry KL, El-Bahrawy MA, Coulson P, Etter JL, LaVigne-Mager K, Andress J, Grube M, Fischer A, Neudeck N, Robertson G, Farrell R, Barlow E, Quinn C, Hettiaratchi A, Casablanca Y, Erber R, Stewart CJR, Tan A, Yu Y, Boros J, Brand AH, Harnett PR, Kennedy CJ,</p>	<p>MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.</p>	<p>Virchows Arch</p>	<p>480(4)</p>	<p>855-871</p>	<p>2021</p>

Nevins N, Morgan T, Fasching PA, Vergote I, Swerdlow AJ, Candido Dos Reis FJ, Maxwell GL, Neuhausen SL, Barquin-Garcia A, Modugno F, Moysich KB, Crowe PJ, <u>Hirasawa A</u> , Heitz F, Karlan BY, Goode EL, Sinn P, Horlings HM, Høgdall E, Sundfeldt K, Kommoss S, Staebler A, Wu AH, Cohen PA, DeFazio A, Lee CH, Steed H, Le ND, Gayther SA, Lawrenson K, Pharoah PDP, Konecny G, Cook LS, Ramus SJ, Kelemen LE, Köbel M.					
Makabe T, Yamagami W, <u>Hirasawa A</u> , Miyabe I, Wakatsuki T, Kikuchi M, Takahashi A, Noda J, Yamamoto G, <u>Aoki D</u> , Akagi K.	Incidence of germline variants in Lynch syndrome-related genes among Japanese endometrial cancer patients aged 40 years or younger.	Int J Clin Oncol	26(9)	1767-1774	2021
Iwasa-Inoue N, Nomura H, Kataoka F, Chiyoda T, Yoshihama T, Nanki Y, Sakai K, Kobayashi Y, Yamagami W, Morisada T, <u>Hirasawa A</u> , <u>Aoki D</u> .	Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients.	Int J Clin Oncol	27(2)	441-447	2021
Taniguchi K, Yanai H, Kaji T, Kubo T, Ennishi D, <u>Hirasawa A</u> , Yoshino T.	Secretory carcinoma of the skin with lymph node metastases and recurrence in both lungs: A case report.	J Cutan Pathol	48(8)	1069-1074	2021
Inoue H, Tomida S, Horiguchi S, Kato H, Matsuoka H, Sanehira E, Matsuoka M, Yanai H, <u>Hirasawa A</u> , Toyooka S.	Best practices for the extraction of genomic DNA from formalin-fixed paraffin-embedded tumor tissue for cancer genomic profiling tests.	Pathol Int	71(5)	360-364	2021

Sakurai Y, Kikuchi S, Shigeyasu K, Kakiuchi Y, Tanaka T, Umeda H, Sakamoto M, Takeda S, Yano S, Futagawa M, Kato F, Sogawa R, Yamamoto H, Kuroda S, Kondo Y, Teraishi F, Kishimoto H, Nishizaki M, Kagawa S, <u>Hirasawa A</u> , Fujiwara T.	SMAD4 Germline Pathogenic Variant-Related Gastric Juvenile Polyposis with Adenocarcinoma Treated with Laparoscopic Total Gastrectomy: A Case Report.	Am J Case Rep	22	e932241	2021
Nakano Y, Iwata N, Ogura-Ochi K, Hasegawa K, <u>Hirasawa A</u> , Otsuka F.	Preclinical diagnosis and identification of the chimeric CYP11B1/CYP11B2 gene in two pediatric cases of a Japanese family with glucocorticoid-remediable aldosteronism.	Hypertens Res	44(7)	891-893	2021
Abe K, Ueki A, Urakawa Y, Kitago M, Yoshihama T, Nanki Y, Kitagawa Y, <u>Aoki D</u> , Kosaki K, <u>Hirasawa A</u> .	Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report.	Hered Cancer Clin Pract	19(1)	5	2021
Yoshihama T, <u>Hirasawa A</u> , Sugano K, Yoshida T, Ushiana M, Ueki A, Akahane T, Nanki Y, Sakai K, Makabe T, Yamagami W, Susumu N, Kameyama K, Kosaki K, <u>Aoki D</u> .	Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome.	Int Can Conf J	10	6-10	2021
平沢 晃.	ポストコロナ時代の産婦人科医療 遺伝医療.	産婦人科の実際	70(7)	741-744	2021
中田英二, 藤原智洋, 国定俊之, 尾崎敏文, 遠西大輔, 富田秀太, 平沢 晃, 二川摩周, 武田達明.	肉腫におけるがんゲノム医療の意義.	別冊整形外科	79	75-83	2021

坂井美佳,竹原和宏, 平沢 晃.	がん遺伝子パネル検査を行う にあたっての患者説明.	臨床婦人科産科	75(4)	354-361	2021
坂井美佳,竹原和宏, 平沢 晃.	コンパニオン診断を行うにあた つての患者説明.	臨床婦人科産科	75(4)	362-369.	2021
坂井美佳,平沢 晃.	HBOC~婦人科の立場から	Cancer Board of the Breast	6 (2)	53-57	2021
平沢 晃	婦人科診療におけるがんゲノ ム医療およびコンパニオン診 断と生殖細胞系列バリエントの 扱い	日本産科婦人科学 会雑誌	73(4)	559-565	2021
平沢 晃.	遺伝性乳癌卵巣癌症候群	日本医事新報	5058	40-41	2021
平沢 晃.	生殖細胞系列バリエントの扱 いとその考え方	腫瘍内科	27(1)	43-46	2021
坂井美佳,竹原和宏, 平沢 晃.	婦人科腫瘍領域における遺伝 診療総論	産科と婦人科	88(1)	65-72	2021
Yoshida R, Hagio T, Kaneyasu T, Gotoh O, Osako T, Tanaka N, Amino S, Yaguchi N, Nakashima E, Kitagawa D, Ueno T, Ohno S, Nakajima T, Nakamura S, Miki Y, Hirota T, Takahashi S, Matsuura M, Noda T, Mori S	Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample	Cancer Sci	112	1310-1319	2021

Kikuchi J, Takeda K, Tanabe H, Hatanaka K, Ohhara Y, Amano T, Hatanaka KC, Hatanaka Y, Mitamura T, Yabe I, Endoh A, Komatsu Y, Matsuno Y, Manabe A, <u>Sakurai A</u> , Takahashi M, Naruse H, Torimoto Y, Dosaka-Akita H, Kinoshita I.	Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers with no standard drug therapy in Hokkaido area of Japan.	Jpn J Clin Oncol	51	753-761	2021
櫻井晃洋	ゲノム情報に基づいた先制医療の時代へ.	腎泌尿器疾患予防学会誌	28	13-16	2020
Abe K, Ueki A, Urakawa Y, Kitago M, Yoshihama T, Nanki Y, Kitagawa Y, <u>Aoki D</u> , Kosaki K, Hirasawa A	Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report.	Hered Cancer Clin Pract	19	5	2021
Kobayashi Y, Hirasawa A, Chiyoda T, Ueki A, Masuda K, Misu K, Kawaida M, Hayashi S, Kataoka F, Banno K, Kosaki K, <u>Aoki D</u>	Retrospective evaluation of risk-reducing salpingo-oophorectomy for <i>BRCA1/2</i> pathogenic variant carriers among a cohort study in a single institution.	Jpn J Clin Oncol	51	213-217	2021
Akagi K, Oki E, Taniguchi H, Nakatani K, <u>Aoki D</u> , Kuwata T, Yoshino T	Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors.	Cancer Sci	112	1105-1113	2021

Kaneyasu T, Mori S, Yamauchi H, Ohsumi S, Ohno S, <u>Aoki D</u> , Baba S, Kawano J, Miki Y, Matsumoto N, Nagasaki M, Yoshida R, Akashi-Tanaka S, Iwase T, Kitagawa D, Masuda K, Hirasawa A, Arai M, Takei J, Ide Y, Gotoh O, Yaguchi N, Nishi M, Kaneko K, Matsuyama Y, Okawa M, Suzuki M, Nezu A, Yokoyama S, Amino S, Inuzuka M, Noda T, Nakamura S	Prevalence of Disease-Causing Genes in Japanese Patients With <i>BRCA1/2</i> -wildtype Hereditary Breast and Ovarian Cancer Syndrome.	NPJ Breast Cancer	6	25	2020
Yoshihara K, Enomoto T, <u>Aoki D</u> , Watanabe Y, Kigawa J, Takeshima N, Inomata H, Hattori K, Jinushi M, Tsuda H, Sugiyama T	Association of <i>gBRCA1/2</i> mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study.	Cancer Sci	111	3350-3358	2020
Saotome K, Chiyoda T, Aimon E, Nakamura K, Tanishima S, Nohara S, Okada C, Hayashi H, Kuroda Y, Nomura H, Susumu N, Iwata T, Yamagami W, Kataoka F, Nishihara H, <u>Aoki D</u>	Clinical implications of next-generation sequencing-based panel tests for malignant ovarian tumors.	Cancer Med	9(20)	7407-7417	2020
Okano M, Nomizu T, Tachibana K, Nagatsuka M, Matsuzaki M, Katagata N, Ohtake T, Yokoyama S, Arai M, Nakamura S.	The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database.	J Hum Genet	66	307-314	2021
Yoshimura A, Yokoyama S, Iwata H, Takaiso N, Nomizu T, <u>Arai M</u> , Nakamura S.	Incidence of contralateral and ipsilateral breast cancers and prognosis in <i>BRCA1/2</i> pathogenic variant carriers based on the Japanese HBOC Consortium registration.	J Hum Genet	66	379-387	2021

Inuzuka M, Watanabe C, Yokoyama S, Kuwayama T, Akashi-Tanaka S, Arai M, Nakamura S; Registration Committee of the Japanese HBOC consortium.	A Retrospective Analysis of the Relationship Between the Result of BRCA1/2 Genetic Testing and Surgical Method Selection in Japan.	Clin Breast Cancer	21	e48-e52	2020
Mitamura T, Sekine M, Arai M, Shibata Y, Kato M, Yokoyama S, Yamashita H, Watari H, Yabe I, Nomura H, Enomoto T, Nakamura S; Registration Committee of the Japanese HBOC Consortium.	Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.	Jpn J Clin Oncol	50	1380-1385	2020
戸崎光宏	ゲノム情報に基づく予防医学における画像診断の役割について	INNERVISION	35-8	2-4	2020
村上和香奈、戸崎光宏	ハイリスク女性に対する乳がん画像診断—米国の現状から考える個別化サーベイランスとは	INNERVISION	35-8	5-8	2020
Ueki A, <u>Hirasawa A.</u>	Molecular Features and Clinical Management of Hereditary Gynecological Cancers.	Int J Mol Sci	21	9504	2020
Kaneyasu T, Mori S, Yamauchi H, Ohsumi S, Ohno S, Aoki D, Baba S, Kawano J, Miki Y, Matsumoto N, Nagasaki M, Yoshida R, Akashi-Tanaka S, Iwase T, Kitagawa D, Masuda K, <u>Hirasawa A</u> , Arai M, Takei J, Ide Y, Gotoh O, Yaguchi N, Nishi M, Kaneko K, Matsuyama Y, Okawa M, Suzuki M, Nezu A, Yokoyama S, Amino S, Inuzuka M, Noda T, Nakamura S.	Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome.	NPJ Breast Cancer	6	25	2020

Kobayashi Y, <u>Hirasawa A</u> , Chiyoda T, Ueki A, Masuda K, Misu K, Kawaida M, Hayashi S, Kataoka F, Banno K, Kosaki K, Aoki D.	Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution.	Jpn J Clin Oncol	51	213-217	2020
Tsuchiya M, Yamada T, Akaishi R, Hamanoue H, <u>Hirasawa A</u> , Hyodo M, Imoto I, Kosho T, Kurosawa K, Murakami H, Nakatani K, Nomura F, Sasaki A, Shimizu K, Tamai M, Umemura H, Watanabe A, Yoshida A, Yoshihashi H, Yotsumoto J, Kosugi S.	Attitudes toward and current status of disclosure of secondary findings from next-generation sequencing: a nation-wide survey of clinical genetics professionals in Japan.	J Hum Genet	65	1045-1053	2020
Naito Y, Mishima S, Akagi K, Igarashi A, Ikeda M, Okano S, Kato S, Takano T, Tsuchihara K, Terashima K, Nishihara H, Nishiyama H, Hiyama E, <u>Hirasawa A</u> , Hosoi H, Maeda O, Yatabe Y, Okamoto W, Ono S, Kajiyama H, Nagashima F, Hatanaka Y, Miyachi M, Kodera Y, Yoshino T, Taniguchi H.	Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.	Int J Clin Oncol.	25	403-417	2020
Mishima S, Taniguchi H, Akagi K, Baba E, Fujiwara Y, <u>Hirasawa A</u> , Ikeda M, Maeda O, Muro K, Nishihara H, Nishiyama H, Takano T, Tsuchihara K, Yatabe Y, Kodera Y, Yoshino T.	Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.	Int J Clin Oncol.	25	217-239	2020
中田はる佳, <u>平沢 晃</u>	フィンランドにおけるゲノム情報・医療情報の利活用のための基盤整備.	遺伝子医学	10	151-157	2020

平沢 晃	がんゲノム医療と遺伝性腫瘍	日本産科婦人科学会雑誌	72	1710-1712	2020
坂井美佳,竹原和宏, 平沢 晃.	がん遺伝子パネル検査結果の 取り扱いと解釈 Germline findingsの取り扱い	産婦人科の実際	69	721-727	2020
柳井広之,都地知紘, 谷口恒平,西田賢司, 井上博文,松岡博美, 平沢 晃,河内麻里子, 山本英喜,富田秀 太,遠西大輔.	岡山大学のエキスパートパネ ル. ゲノム医療におけるエキス パートパネル	病理と臨床	38	527-530	2020
平沢 晃	がんクリニカルシーケンスと生 殖細胞系列バリエーションへの対 応	日本婦人科腫瘍学 会雑誌	38	101-105	2020
平沢 晃	卵巣がんに対するコンパニ オン診断の使い方	臨床婦人科産科	74	317-323	2020
平沢 晃	がんゲノム医療と女性ヘルスケ ア	更年期診療update 医学のあゆみ		85-88	2020
中谷 中,平沢 晃, 谷田部 恭,宮地 勇人	がんゲノム医療時代の幕開け	モダンメディア	66	1-23	2020
平沢 晃	がんゲノム医療が婦人科実地 臨床に本格導入される際の留 意点は？	日本医事新報	5008	58-59	2020
平沢 晃.	遺伝性腫瘍とがん予防.	岡山医学会雑誌	131	83-87	2020
平沢 晃	マイクロサテライト不安定性検 査 やさしくわかる産科婦人科 検査マスターブック	産科と婦人科	87	118-120	2020
平沢 晃	がんゲノム医療における遺伝 子パネル検査と遺伝性腫瘍	Urology Today	27	8-12	2020

<u>Yoshida R</u>	Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis	Breast Cancer		2020 Aug 29. doi: 10.1007/s12282-020-01148-2. Epub ahead of print.	2020
------------------	---	---------------	--	--	------